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The genetic basis of undiagnosed muscular
dystrophies and myopathies
Results from 504 patients
ABSTRACT
Objective: To apply next-generation sequencing (NGS) for the investigation of the
genetic basis of undiagnosed muscular dystrophies and myopathies in a very large cohort
of patients.
Methods:We applied an NGS-based platform namedMotorPlex to our diagnostic workflow to test
muscle disease genes with a high sensitivity and specificity for small DNA variants. We analyzed
504 undiagnosed patients mostly referred as being affected by limb-girdle muscular dystrophy or
congenital myopathy.
Results:MotorPlex provided a complete molecular diagnosis in 218 cases (43.3%). A further 160
patients (31.7%) showed as yet unproven candidate variants. Pathogenic variants were found in
47 of 93 genes, and in more than 30% of cases, the phenotype was nonconventional, broadening
the spectrum of disease presentation in at least 10 genes.
Conclusions: Our large DNA study of patients with undiagnosed myopathy is an example of the
ongoing revolution in molecular diagnostics, highlighting the advantages in using NGS as
a first-tier approach for heterogeneous genetic conditions. Neurology® 2016;87:71–76
GLOSSARY
CM 5 congenital myopathy; LGMD 5 limb-girdle muscular dystrophy; MD 5 muscular dystrophy; NGS 5 next-generation
sequencing; NMD 5 neuromuscular disorder.
Muscular dystrophies (MDs)1,2 and congenital myopathies (CMs)3 represent the majority of
inherited neuromuscular disorders (NMDs).4,5
Until the development of next-generation sequencing (NGS), routine molecular diagnosis of
NMDs had been based on a gene-by-gene approach.1,6–8 This time-consuming and expensive
approach9 failed to identify causative variants in more than 40% of cases, detection rates varied
with different genes or conditions, and the size of some large genes, such as TTN or NEB,
hampered routine analysis.
Targeted NGS, which focuses only on specific genes of interest,10 has recently been proposed
as a cost-effective strategy for the molecular diagnosis of heterogeneous disorders.11
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Although different targeted approaches ana-
lyzing genes causing NMDs have been described
in literature,12–14 screening for mutations in all
known muscular disease genes in a large NMD
patient cohort is rare.
Herein, we describe the results obtained in an
extensive study of 504 genetically undiagnosed
patients presenting clinical signs of MD, CM,
or other conditions affecting the muscles. We
report the different diagnostic rate for each clin-
ical condition studied and discuss the advantages
and disadvantages of our strategy, illustrating
some unexpected results as well as its main
limitations.
METHODS Patients and study design. With the help of
the Italian Network of Congenital Myopathies and the Italian
Network of Limb-Girdle Muscular Dystrophy (LGMD), we
collected DNA samples from patients with a clinical diagnosis
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Figure 1 Characteristics of recruited patients
(A) Percentage of male and female patients. (B) Geographical origin of patients. (C) Percentage of patients in 3 different cat-
egories (LGMD, CM, other conditions). (D) Mode of inheritance for the studied conditions. (E) Previous unsuccessful molec-
ular tests performed in prescreened patients. CM 5 congenital myopathy; LGMD 5 limb-girdle muscular dystrophy.
72 Neurology 87 July 5, 2016
of a nonspecific myopathy, congenital myopathy, proximal
muscle weakness, or LGMD. Genes that are universally considered
as genetic causes of nonsyndromic myopathies (table e-1 on the
Neurology® Web site at Neurology.org) were investigated by using
a custom NGS panel, named MotorPlex.15
For each patient, we collected clinical and laboratory data as well
as the results of familial segregation analyses and previous genetic tests.
We included in this study a total of 588 samples from 504
patients and 84 unaffected relatives and analyzed them using 4
different strategies according to genetic transmission and avail-
ability of further samples from relatives. Specifically, in 400 cases
(mainly sporadic), only the proband’s DNA samples were ana-
lyzed; in 50 sporadic cases, trio (n5 31) or duo (n5 19) analysis
was performed. In 54 familial cases, additional samples from
other affected and unaffected family members were analyzed.
Standard protocol approvals, registrations, and patient
consents. All the patients and families provided written
informed consent to the different clinical centers involved in
the Project GUP11006 following the guidelines of Telethon
Foundation, Italy, according to the Declaration of Helsinki.
The Ethics Committee of The Second University of Naples
approved the NGS study protocol.
NGS workflow and sequencing analysis. We prepared
a library according to the manufacturer’s instructions (HaloPlex
Target Enrichment System for Illumina Sequencing; Agilent Tech-
nologies, Santa Clara, CA). Bioanalyzer High Sensitivity DNA
Assay kit (Agilent Technologies) was used to validate and quantify
library preparation. Twenty individual samples were run in a single
lane of a HiSeq1000 system (Illumina Inc., San Diego, CA), gen-
erating 100–base pair paired end reads. Analysis of NGS data was
performed using an in-house pipeline described elsewhere.15,16
RESULTS Patients under study. We collected and
sequenced 588 samples from 504 patients and 84 unaf-
fected relatives. Specifically, 85% of the patients were
Italian (figure 1A), and sex distribution showed that
male patients were predominantly affected (59.6%) (fig-
ure 1B). All patients were classified, according to their
clinical phenotype, as affected by LGMD (51.2%), CM
(32.5%), or other clinical conditions (16.3%), includ-
ing, among others, distal myopathy (3.8%), isolated
hyperCKemia (3.4%), and metabolic myopathy
(1.2%) (figure 1C, table e-2).
Most patients were sporadic cases (81%), while 96
were familial, including 37 dominant and 59 recessive
forms (figure 1D).
The vast majority (.90%) of samples collected had
previously been tested unsuccessfully (figure 1E),
according to the observed phenotype.
Molecular findings and clinical evaluation. In view of
the high number of variants identified in each patient,
bioinformatic filters were applied to prioritize variant
type (missense, indel, stopgain, or stoploss), frequency
in public and internal databases, and annotation as
disease-associated variants were used. In addition, the
correspondence of molecular findings with clinical
presentation, age at onset, and segregation in familial
cases was critically reevaluated. On the basis of these
procedural steps, 218 cases obtained a diagnosis,
showing known disease-associated variants, or variants
of a likely pathogenicity, or variants predicted to affect
function in genes corresponding to clinical suspicions.
The majority of these patients (76%) showed already
described or clear loss-of-function mutations, and
most of the variants identified (65%) were missense
(figure 2). Only one mutation causing the loss of the
stop codon was identified and a single homozygous
large deletion in SGCB was detected.
In 115 patients, LGMD-related genes were consid-
ered causative of the observed phenotype (table 1).
Specifically, the CAPN3 gene was responsible for 22
cases, the sarcoglycan genes for 20 cases, and theDYSF
and ANO5 genes for 15 cases, each.
Among the remaining genes (table 2), RYR1 caused
the highest number of cases (n 5 25), followed by
NEB, LAMA2, and MYH7.
A total of 160 cases (83 LGMD, 50 CM, and 27
with other conditions) are still under investigation
since a clear and complete explanation of the observed
Figure 2 Diagnostic rate and molecular results
(A) Definitive diagnosis was obtained in 43.2% of patients. In addition, 31.8% of patients
showed variants that required further characterization. (B) Type of causativemutations iden-
tified in diagnosed patients: missense (64.9%), small indels (12.2%), splice-site variants
(11.9%), and nonsense mutations (10.4%).
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phenotype has not been identified. In most of these
cases, a single variant in at least one gene fitting the
clinical conditions of the patients was detected: more
than 250 variants were identified, including 128 pre-
viously described variants discovered in 98 patients.
In the 126 cases with no molecular findings fitting
the observed phenotype, a large number of variants of
uncertain significance were identified. Although we
cannot exclude a possible role for some of these, other
additional and undetectable genetic changes may
cause the phenotype.
Of note, only 19% of the patients with LGMD
showed no putative deleterious variants. In contrast,
almost 31% of patients with CM and 32% of patients
with other clinical conditions presented no putative
causative variants.
DISCUSSION In recent years, NGS has totally trans-
formed the approach to the study of NMDs,17 and
a number of diagnostic platforms have been devel-
oped for the simultaneous analysis of several different
genes.13,14,17,18 However, all previously published re-
ports have shown a proof of concept on a limited
number of patients only.
Herein, we report the results of a large study of an
NMD cohort. The use of stringent bioinformatic fil-
ters to obtain relevant molecular data15,16 and a careful
reevaluation of clinical presentation and laboratory
findings allowed us to identify putative causative mu-
tations in 218 cases, representing slightly more than
43% of our cohort.
This ratio reflects the large number of prescreened
samples in our cohort. As previously mentioned, sam-
ples from more than 90% of our patients had already
been tested by Sanger sequencing or other laboratory
techniques. Focusing on LGMD cases, for example,
the number of patients with dysferlinopathy or calpain-
opathy, accounting for more than 40% of LGMDs in
Italy,19,20 is small because of extensive studies previously
performed on these genes. In our screening analysis, 37
cases, corresponding to 14% of patients with LGMD
recruited, showed causative mutations in theDYSF and
CAPN3 genes. This large difference (40% vs 14%)
reflects the filtering out of patients with DYSF and
CAPN3 mutations. Further molecular tests, including
segregation analyses or functional tests, on the 160 cases
Table 1 LGMD genes22
Disease Locus Gene
No. of
patients
LGMD1B 1q22 LMNA 3
LGMD1C 3p25.3 CAV3 2
LGMD2A 15q15 CAPN3 22
LGMD2B 2p13.2 DYSF 15
LGMD2C 13q12 SGCG 4
LGMD2D 17q21 SGCA 10
LGMD2E 4q12 SGCB 6
LGMD2G 17q12 TCAP 1
LGMD2H 9q33.1 TRIM32 1
LGMD2I 19q13.3 FKRP 7
LGMD2J 2q24.3 TTN 5
LGMD2K 9q34.1 POMT1 1
LGMD2L 11p13 ANO5 15
LGMD2M 9q31 FKTN 2
LGMD2N 14q24 POMT2 6
LGMD2R 2q35 DES 1
LGMD2S 4q35.1 TRAPPC11 2
LGMD2T 3p21 GMPPB 2
LGMD2V 17q25 GAA 10
Abbreviation: LGMD 5 limb-girdle muscular dystrophy.
Table 2 Other myopathy genes
Locus Gene
No. of
patients
1q42.13 ACTA1 2
1p21 AGL 2
21q22.3 COL6A2 4
2q37 COL6A3 1
11q22.3–q23.1 CRYAB 1
Xp21.2 DMD 7
19p13.2 DNM2 5
Xq28 EMD 1
7q32 FLNC 4
17q25.2–q25.3 GLA 1
3p12 GNE 3
3p22.1 GTDC2 1
3q24 GYG1 1
12q13.2 ITGA7 2
6q22–q23 LAMA2 8
Xq28 MTM1 5
17p13.1 MYH2 1
14q12 MYH7 8
5q31 MYOT 1
2q23.3 NEB 9
11q12–q13.2 PYGM 3
20p13 RYR1 25
1p36.13 SEPN1 2
18p11.32 SMCHD1 1
6q25 SYNE1 1
14q23.2 SYNE2 1
9p13 TPM2 1
1q21.2 TPM3 2
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still under investigation could increase the detection
rate by at least 10% to 15%, according to our conser-
vative estimate.
One key finding from our study was the identifi-
cation of patients with an LGMD phenotype carrying
variants in causative genes not typically associated
with LGMD. In particular, late-onset Pompe disease,
resulting from mutations in the GAA gene,21 was
diagnosed in 10 patients. In our screening assay,
GAA represents the fourth most common cause of
a recessive limb-girdle myopathy that might mimic
an LGMD,22 suggesting that the difficulty in making
a differential diagnosis between LGMD and late-
onset Pompe disease may be underestimated.
Similarly, causative variants in patients with
LGMD were identified in genes causing congenital
MD (GMPPB or LAMA2), Bethlem myopathy
(COL6), and other metabolic myopathies (AGL,
GYG1, and PYGM).
We also detected seven causative variants in the
DMD gene, involved in Becker muscular dystrophy.23
The enormous size of the DMD gene had always
hampered analysis by Sanger sequencing24 and the
prevalence of Becker muscular dystrophy is probably
underestimated.
Of note, the diagnostic rate was higher for the
LGMD cohort of patients than for both the CM
group and for patients with other clinical conditions
(figure 3). The molecular diagnosis of CM may have
been hindered by the significant clinical overlap
between CM and other NMDs including congenital
MD, congenital myasthenic syndromes, metabolic
myopathies, spinal muscular atrophy, and Prader-
Willi syndrome, which can all be characterized by
marked muscle weakness and/or hypotonia.8 Motor-
Plex is in fact unable to provide a molecular diagnosis
for most of these disorders, and a subsequent diag-
nostic step is necessary to exclude them.
Interpreting the molecular data obtained in patients
with “other clinical conditions” is much more complex
as some of them present with a mild clinical pheno-
type. For example, of the 17 patients with isolated
hyperCKemia, a genetic diagnosis was only obtained
in 2 cases, as expected. However, 7 of them had at least
one well-known heterozygous mutation in a gene that
might possibly be responsible for the disorder.
We conducted a critical reevaluation of all the
molecular data, looking for possible “double trouble,”
i.e., 2 independent molecular events, each responsible
for a specific phenotype, causing the observed clinical
condition. No clear “double trouble” was identified.
However, in 72 patients with a complete diagnosis,
a further, already described, causative variant in a reces-
sive gene was detected, suggesting that it is quite a com-
mon finding.
Our study represents an important first step toward
the identification of novel disease-causing genes. Some
of the unsolved cases could in fact be attributable to pre-
viously undescribed causative genes.25 Whole exome
sequencing or whole genome sequencing may therefore
be crucial tools to discover novel NMD genes.26,27
The combined use of other tools, such as CGH-
array28,29 or RNA-Seq,30 to detect copy number varia-
tions and/or other variants missed by NGS is a neces-
sary subsequent step to increase the diagnostic rate of
NMDs.
Our extensive study confirms the importance of
NGS screening as a powerful tool in the diagnostic
workflow for NMD. In light of the speed, efficacy,
and ever-decreasing cost of this approach, we predict
that it will become a universal first-tier test for hetero-
geneous genetic conditions.
AUTHOR CONTRIBUTIONS
Drs. Savarese, Di Fruscio, Torella, Mutarelli, Marwah, Garofalo, Giugliano,
Del Vecchio Blanco, Esposito, Piluso, and Nigro contributed to the
acquisition, analysis and interpretation of data. Drs. Fiorillo, Magri,
Fanin, Ruggiero, G. Ricci, Astrea, Passamano, Ruggieri, Ronchi, Tasca,
D’Amico, Janssens, Farina, Sanpaolo, D’Ambrosio, Petillo, Musumeci,
Rodolico, Messina, Evilä, Hackman, Filosto, Di Iorio, Siciliano, Mora,
Maggi, Minetti, Sacconi, Santoro, Claes, Vercelli, Mongini, E. Ricci,
Gualandi, Tupler, De Bleecker, Udd, Toscano, Moggio, Pegoraro,
Bertini, Mercuri, Angelini, Santorelli, Politano, Comi, Bruno, and Nigro
contributed to the selection and clinical evaluation of patients and to the
analysis and interpretation of data. Drs. Savarese, Angelini, Santorelli,
Politano, Comi, Bruno, and Nigro contributed to the design and con-
ceptualization of the study.
Figure 3 Distribution of the 504 patients tested according to clinical
phenotype and molecular findings
A total of 125 patients (48.4%) with LGMD received a molecular diagnosis, 83 (32.2%) are
still under consideration, and in 50 patients (19.4%), no clear causative variants were de-
tected. A total of 64 patients (39%) with CM received a molecular diagnosis, 50 (30.5%)
are still under investigation, and 50 (30.5%) showed no causative variations. A total of 29
patients (35.4%) with other clinical conditions received a molecular diagnosis, 27 (32.9%)
are to be further investigated, and in 26 patients (31.7%), no causative variants were iden-
tified. CM 5 congenital myopathy; LGMD 5 limb-girdle muscular dystrophy.
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